2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161072
    CSC-6 98%
    CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC50 value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models.
    CSC-6
  • HY-161107
    OX04529 98%
    OX04529 (compound 69) is a potent, selective and orally active agonist of GPR84. OX04529 inhibits FSK-induced cAMP production with an EC50 of 0.0185 nM. OX04529 displayed excellent potency, high G-protein signaling bias.
    OX04529
  • HY-161120
    NLRP3-IN-27 2997864-57-8 98%
    NLRP3-IN-27 is a selective NLRP3 inhibitor with a IC50 value of 0.55 μM. NLRP3-IN-27 can be used in the study of inflammation and immunity.
    NLRP3-IN-27
  • HY-161131
    Lenalidomide 4'-alkyl-C3-azide 2399455-71-9 98%
    Lenalidomide 4'-alkyl-C3-azide (compound 4a) is a click chemical modified Lenalidomide (HY-A0003) that can be used to synthesize PROTACs. Lenalidomide is an orally active immunomodulator and a ligand for the ubiquitin E3 ligase cereblon (CRBN). Lenalidomide 4'-alkyl-C3-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition reactions (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    Lenalidomide 4'-alkyl-C3-azide
  • HY-161139
    JAK1-IN-14 98%
    JAK1-IN-14 (Compound 12a) is a potent and selective JAK1 inhibitor. JAK1-IN-14 inhibits JAK1 and JAK2 with an IC50 value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases.
    JAK1-IN-14
  • HY-161147
    COX-2-IN-37 98%
    COX-2-IN-37 (compound 11) is a potent and selective COX-2 inhibitor. COX-2-IN-37 has strong antioxidant activity with an IC50 of 33.0 μg/mL.
    COX-2-IN-37
  • HY-161155
    HDAC6-IN-31 98%
    HDAC6-IN-31 (compound 8m) is a selective HDAC6 inhibitor, with the IC50 value of 0.026 μM, that significantly inhibits the production and release of pro-inflammatory cytokines. While HDAC6 is critically involved in the activation of inflammasomes, HDAC6-IN-31 has the potential to inhibit NLRP3 inflammasome-driven inflammatory diseases. HDAC6-IN-31 also inhibits glioblastoma cell migration.
    HDAC6-IN-31
  • HY-161240
    MAO-B-IN-30 82973-15-7 98.53%
    MAO-B-IN-30 (compound IS7) is a potent, selective and cross the blood-brain barrier MAO-B inhibitor with IC50 values of 19.176, 0.082 µM for MAO-A and MAO-B, respectively. MAO-B-IN-30 shows antiproliferative activity and non-cytotoxic. MAO-B-IN-30 reduces TNF-alpha, IL-6, NF-kB levels. MAO-B-IN-30 has the potential for the research of Parkinson's disease.
    MAO-B-IN-30
  • HY-161249
    Vanin-1-IN-4 2173134-02-4 98%
    Vanin-1-IN-4 (compound (S)-1) is vanin-1 inhibitor with a chiral methyl substituent, with profils as potent drug-candidate but exist as an amorphous solid.
    Vanin-1-IN-4
  • HY-161255
    3,4-DAA 2117759-07-4 98%
    3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4+CD25+ T cells expression. 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide.
    3,4-DAA
  • HY-161259
    JAK-IN-36 98%
    JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC50 value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases.
    JAK-IN-36
  • HY-161266
    COX-2/NLRP3-IN-1 3057274-61-7 98%
    COX-2/NLRP3-IN-1 (Compound 6k) is a COX-2/NLRP3 inhibitor with a IC50 of 1.53 μM for COX-2. COX-2/NLRP3-IN-1 exerts anti-inflammatory effects by inhibiting the NF-κB/NLRP3 signaling pathway.
    COX-2/NLRP3-IN-1
  • HY-161315
    15-LOX-IN-1 98%
    15-LOX-IN-1 (Compound 7c) is a 15-LOX inhibitor with a IC50 value of 1.92 μM. 15-LOX-IN-1 has anti-inflammatory activity.
    15-LOX-IN-1
  • HY-161329
    NLRP3-IN-32 98%
    NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling.
    NLRP3-IN-32
  • HY-161333
    ADS031 98%
    ADS031, a histamine H3R antagonist, displays 12.5 nM affinity at the hH3R and the highest inhibitory activity against AChE (IC50 = 1.537 μM).
    ADS031
  • HY-161342
    CTSL/CAPN1-IN-2 2410075-64-6 98%
    CTSL/CAPN1-IN-2 (Compound 14b) is an orally active inhibitor of both CTSL and CAPN1, with IC50 values of 6.88 nM and 347.6 nM, respectively. CTSL/CAPN1-IN-2 possesses anti-inflammatory properties and favorable pharmacokinetic characteristics. CTSL/CAPN1-IN-2 exhibits broad-spectrum antiviral activity against coronaviruses by blocking viral entry.
    CTSL/CAPN1-IN-2
  • HY-161343
    HDL-16 2373280-36-3 99.19%
    HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function.
    HDL-16
  • HY-161349
    LTA4H-IN-4 98%
    LTA4H-IN-4 (compound 3) is an orally active LTA4H inhibitor. The IC50 value of LTA4H-IN-4 for hERG is 156 μM. LTA4H-IN-4 can be used in inflammation related studies.
    LTA4H-IN-4
  • HY-161354
    JAK3 covalent inhibitor-2 2664050-97-7 98%
    JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC50=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability.
    JAK3 covalent inhibitor-2
  • HY-161364
    Antibacterial agent 200 98%
    Antibacterial agent 200 (pyridyl HH 7), a unique hydrazyl hydroxycoumarin (HH), has strong antibacterial efficacy and broad antibacterial spectrum with MIC values ranging from 0.5 to 32 μg/mL for Gram-positive and Gram-negative bacteria. Antibacterial agent 200 exhibits a good inhibition against Pseudomonas aeruginosa 27853 with a low MIC value of 0.5 μg/mL. Antibacterial agent 200 can eradicate the integrity of bacterial membrane, result in the leakage of intracellular proteins, and interact with bacterial DNA gyrase via non-covalent binding.
    Antibacterial agent 200
Cat. No. Product Name / Synonyms Application Reactivity